临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
2'-Deoxy-5-Fluorocytidine
中文名称:5-氟脱氧胞苷
CAS号:10356-76-0
分子式: C9H12FN3O4 分子量: 245.21
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Lynch Syndrome; Recurrent Uterine Corpus Carcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer
研究机构: Gynecologic Oncology Group; National Cancer Institute (NCI); GOG Foundation
研发日期: Jan-00
研发阶段: --
2'-Deoxy-5-fluorocytidine (5-fluoro-2(')-deoxycytidine, FCdR), a pyrimidine analog, is a DNA methyltransferase (DMNT) inhibitor currently in clinical trials for solid tumors.
TAK-733
中文名称:TAK733抑制剂
CAS号:1035555-63-5
分子式: C17H15F2IN4O4 分子量: 504.23
产品形式: free base
研发状态: Withdrawn
研发用途: Advanced Nonhematologic Malignancies
研究机构: Millennium Pharmaceuticals Inc.
研发日期: Aug-13
研发阶段: Phase 1
TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.
AZD4547
CAS号:1035270-39-3
分子式: C26H33N5O3 分子量: 463.57
产品形式: free base
研发状态: Completed
研发用途: Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion; Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion
研究机构: Assistance Publique - Hôpitaux de Paris
研发日期: Sep-15
研发阶段: Phase 1 : Phase 2
AZD4547 (ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.
Onvansertib (NMS-P937)
中文名称:4,5-二氢-1-(2-羟基乙基)-8-[[5-(4-甲基-1-哌嗪基)-2-(三氟甲氧基)苯基]氨基]-1H-吡唑并[4,3-h]喹唑啉-3-甲酰胺
CAS号:1034616-18-6
分子式: C24H27F3N8O3 分子量: 532.52
产品形式: free base
研发状态: Active not recruiting
研发用途: Colorectal Cancer; Metastatic Colorectal Cancer
研究机构: Cardiff Oncology
研发日期: March 17 2023
研发阶段: Phase 2
Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1.
Ceritinib (LDK378)
中文名称: 色瑞替尼
CAS号:1032900-25-6
分子式: C28H36ClN5O3S 分子量: 558.14
产品形式: free base
研发状态: Completed
研发用途: Non-Small-Cell Lung Cancer
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: August 21 2015
研发阶段: Phase 2
Ceritinib (LDK378) is a potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays. Ceritinib (LDK378) also inhibits IGF-1R, InsR, STK22D and FLT3 with IC50 of 8 nM, 7 nM, 23 nM and 60 nM, respectively. Phase 3.
GSK1292263
中文名称:5-[[[1-(3-异丙基-1,2,4-噁二唑-5-基)-4-哌啶基]甲基]氧基]-2-[4-(甲磺酰基)苯基]吡啶
CAS号:1032823-75-8
分子式: C23H28N4O4S 分子量: 456.56
产品形式: free base
研发状态: Completed
研发用途: Diabetes Mellitus Type 2
研究机构: GlaxoSmithKline
研发日期: April 14 2010
研发阶段: Phase 1
GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. Phase 2.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
